GE Healthcare announced U.S. FDA 510(k) clearance of SIGNA 7.0T magnetic resonance imaging (MRI) scanner. With a magnet approximately five times more powerful than most clinical systems, SIGNA 7.0T can image anatomy, function, metabolism and microvasculature in the brain and joints with incredible resolution and detail.

November 12, 2020 — GE Healthcare announced U.S. FDA 510(k) clearance of its SIGNA 7.0T magnetic resonance imaging (MRI) scanner. With a magnet approximately five times more powerful than most clinical systems, SIGNA 7.0T can image anatomy, function, metabolism and microvasculature in the brain and joints with incredible resolution and detail. This new system can be used for both research and clinical purposes to support a broad range of investigations across neurologic and musculoskeletal diseases.  

With a powerful 7.0 tesla magnet at its core, SIGNA 7.0T combines a broad range of advanced technology, imaging methods, and years of GE Healthcare experience into a new imaging tool. The completely new SIGNA 7.0T features UltraG gradient technology, GE’s most powerful whole-body gradient coil, to meet the demands of ultra-high field imaging speed and resolution, advanced diffusion, and functional brain imaging.

This system also features GE’s latest SIGNAWorks software platform with state-of-the-art applications such as deep learning-based tools like AIR x brain for automated slice positioning and Silent MR imaging, enabling seamless protocol translation between GE MR systems. In addition, SIGNA 7.0T is equipped with Precision RF transmit and receive architecture to enable improved image quality and enable development in parallel transmit. This system also provides a unique platform for advanced knee and cartilage imaging, allowing for ultra-high-resolution anatomical visualization as well as research capabilities to measure quantitative changes in anatomy due to disease.

“We are thrilled to add SIGNA 7.0T to our portfolio,” said Jie Xue, president and CEO of GE Healthcare MR. “This new scanner is a critical tool in research for neurological disorders like Alzheimer’s disease and mild traumatic brain injury. Now clinicians will have access to the power of ultra-high field imaging combined with the ultra-high-performance gradients to translate research advances into new clinical diagnostic tools and potential treatment options.”

For more information: www.gehealthcare.com

 

Related 7T content:

FDA Clears First 7T MRI System, Magnetom Terra

 


Related Content

News | Digital Pathology

March 29, 2026 — Leica Microsystems has introduced the Viventis SCAPE light sheet microscope. Viventis SCAPE enables ...

Time April 01, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
News | Radiology Business

March 1, 2026 — A new study from the Harvey L. Neiman Health Policy Institute found that practice turnover (i.e ...

Time March 19, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | FDA

Mar. 9, 2026 — GE HealthCare's View, the powerful viewer within the Genesis Radiology Workspace, has received 510(k) ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
Subscribe Now